VITASANG

The potential market for Vitasang is enormous, with end users including hospitals, blood banks and the military. Added to this, Rejveusol has no active competitor. Therefore, just considering the 56% of blood in blood banks older than 14 days, translates to a $15.4 Billion market per year not yet being serviced... Blood rapidly decays upon storage and there is currently no other rejuvenation solution that can be used to extend its shelf life. Old blood (> 9 days old) begins to collect changes to red blood cells (RBCs) that negatively affective their ability to facilitate blood flow and deliver oxygen (called a "storage lesion"), leading to the generation of harmful waste products and increasing morbidity... Rejuvesol is the only FDA-approved product to rejuvenate stored RBCs and the only current technology capable of modifying RBC quality after exhibiting a storage lesion.

Also known as: Vitasang Limited, VITASANG LTD.

Primary location: New Orleans United States